Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment
$RENB Also Secures Plus $15 Million in New Equity to Support its Operations Towards Revolutionizing Healthcare
• Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.
• Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
• Definitive Merger Agreement with BioSymetrics to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond.
• $15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
• 2025 Shareholder Update Issued from CEO.
• Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
• Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
• Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
• Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
On February 26th RENB announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
At the core of this collaboration is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics' advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into the RENB workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, RENB will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
For more information on BioSymetrics visit: www.biosymetrics.com.
$15 Million in New Equity Committed
RENB has also announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
David Weinstein, Chief Executive Officer of Renovaro, commented, 'We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.'
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
RENB recently signed a binding letter of intent to acquire Predictive Oncology (NASDAQ: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing. Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for DCCV RENB will attend the American Association for Cancer Research Annual Meeting in April 2025.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: Send Email
Phone: 732-780-5036
Address: 2080 Century Park East Suite 906
City: Los Angeles
State: California
Country: United States
Website: www.renovarobio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Better Cybersecurity Stock: CrowdStrike or SentinelOne?
Artificial intelligence (AI) may have many benefits, but it's also making it easier for hackers, online criminals, and other digital malefactors to threaten businesses, and those threats are getting more potent. Keeping them at bay requires a lot of funds to be devoted to cybersecurity, making companies like CrowdStrike (NASDAQ: CRWD) and SentinelOne (NYSE: S) excellent investment opportunities. But is there an advantage to buying one over the other now? How do these two approach cybersecurity? Both companies' base products are AI-powered protection platforms that analyze digital activity and learn to spot the threats among the normal activity. They deploy their software to network endpoints -- in other words, laptops, smartphones, and other devices that can access a client's internal network. By protecting these devices, companies make it harder for cyberattackers to gain access to their internal networks, where they might steal sensitive information, delete files, interfere with systems, or even lock them down with ransomware to extort payments from their victims. While endpoint protection is how both companies land clients, each bolsters its offerings with an array of other cybersecurity products that clients can use to create a protection suite tailored to their unique situations. Since these two direct competitors offer highly similar product types, it's hard to declare either a winner on this front from an investor perspective. Winner: Tie. CrowdStrike is much larger than SentinelOne From a sheer size perspective, CrowdStrike is the clear winner. During its fiscal 2026 first quarter, which ended April 30, CrowdStrike's annual recurring revenue (ARR) rose to $4.4 billion. SentinelOne's ARR of $948 million in its fiscal Q1 was less than a quarter of that. While size doesn't always matter, in this case, it does. Because so many more companies use CrowdStrike's platform, it's more likely that any given IT professional will have at least one contact already on its client list. If CrowdStrike is doing a great job with those clients, word will spread, and it will likely receive more serious consideration in future cybersecurity bidding processes. This advantage cannot be understated. Indeed, it's one of the reasons why CrowdStrike's growth has remained strong despite its size. Winner: CrowdStrike SentinelOne is growing more quickly than CrowdStrike, but just barely In terms of growth rates, SentinelOne is slightly outperforming CrowdStrike in this category. However, this should be no surprise because SentinelOne is a much smaller company. In fiscal Q1, SentinelOne's ARR rose 24% year over year, while CrowdStrike's increased 22% year over year. While I will give the point to SentinelOne, it's important to understand that CrowdStrike is growing from a much larger base than SentinelOne, making this close call all the more impressive for CrowdStrike. Winner: SentinelOne Neither company is massively profitable Due to its smaller size and focus on top-line growth, SentinelOne is far from profitable, while CrowdStrike has achieved intermittent profitability (although it reverted to a negative operating margin and a loss in its most recent quarter). S Operating Margin (Quarterly) data by YCharts. SentinelOne is far from breaking even, but CrowdStrike was in this same position about five years ago. There's no reason not to expect SentinelOne to follow a similar path to profitability, but it will take some time. Meanwhile, CrowdStrike should eventually turn a profit again, as it has proven that it can do that. Winner: CrowdStrike SentinelOne looks like a bargain CrowdStrike is leading this battle of the stocks so far, but SentinelOne is about to change the narrative with one jaw-dropping metric. CrowdStrike is the most popular cybersecurity stock in the market, and as a result, it has been bid up to expensive levels. From a price-to-sales (P/S) standpoint (the best metric to use to compare these companies since CrowdStrike flips between profitable and unprofitable, while SentinelOne is years away from profits), CrowdStrike has gotten far more expensive than SentinelOne over the past few years. S PS Ratio data by YCharts. CrowdStrike stock is now five times more expensive than SentinelOne, which is hard to believe, considering they compete in the same industry and are growing at nearly identical rates. This leads me to believe that CrowdStrike's stock has been overly hyped up while SentinelOne has been forgotten. While I'm OK with valuing CrowdStrike at a premium due to its market leadership position, this is far too great a premium to pay. SentinelOne is a dirt-cheap stock, and CrowdStrike is almost too expensive to consider. While I have been a long-term CrowdStrike bull, I'd be a bit cautious about buying the stock at its current lofty valuation. As a result, I think SentinelOne is the better cybersecurity investment right now. Should you invest $1,000 in CrowdStrike right now? Before you buy stock in CrowdStrike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CrowdStrike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
6 hours ago
- Globe and Mail
Has Apple Already Lost the AI Race? There's Another Concern Investors Should Have
In this video, Motley Fool contributors Jason Hall and Jeff Santoro discuss Apple 's (NASDAQ: AAPL) lack of progress with artificial intelligence (AI), along with its history of product introductions and innovation, to break down why trailing in AI may not matter, and not be the biggest thing investors should know about. *Stock prices used were from the afternoon of June 18, 2025. The video was published on June 21, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Jason Hall has no position in any of the stocks mentioned. Jeff Santoro has positions in Apple. The Motley Fool has positions in and recommends Apple. The Motley Fool has a disclosure policy. Jason Hall is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Globe and Mail
7 hours ago
- Globe and Mail
2 Growth Stocks That Could 10x Your Money
If you're looking for stocks with huge return potential, you can increase your chances of success by focusing on companies that operate in a rapidly expanding industry. Great investments are usually made by jumping early on fast-growing companies that have enormous expansion potential for their particular sector. Here are two promising candidates that could potentially grow their share prices 10-fold in the coming years. 1. SoundHound AI Share prices of SoundHound AI (NASDAQ: SOUN) have been volatile, At the time of this writing, the stock is up 342% since the end of 2023. This follows growing demand for the company's conversational voice technology powered by artificial intelligence (AI). SoundHound's revenue more than doubled year over year in the first quarter. This comes after last year's acquisition of Amelia, which expanded SoundHound's technology to customer services across multiple industries, including retail and healthcare. AI is having a major impact on how people order at restaurants and interact with in-car services -- two of SoundHound's biggest markets. As AI's capabilities grow exponentially, demand is surging for SoundHound's voice AI. Over 1,000 new restaurant locations went live with SoundHound in Q1 -- a 10-fold increase over a year ago. The main negative for the company is that it is not earning a profit. In Q1, it reported a non-GAAP (generally accepted accounting principles) loss of $22 million, which is quite large on just $29 million of quarterly revenue. SoundHound generates revenue from product royalties, service subscriptions, and ads on its music identification app. These can be profitable revenue streams, so I wouldn't be too concerned about SoundHound's profitability at this early stage of growth. Keep in mind that SoundHound is not using off-the-shelf AI. Its AI is proprietary, based on 20 years of investment using data from real user interactions. SoundHound also has a strong balance sheet, with $246 million of cash and no debt. The company's growth shows huge market potential for its technology. The AI voice generator market is growing exponentially, expected to increase from $3 billion in 2024 to over $20 billion by 2030, according to MarketsandMarkets. SoundHound's market cap is currently $3.76 billion, with its share price around $9.40. Its market cap has to increase to $37.6 billion to deliver a 10-fold return to investors. This is possible within the next 10 years, considering SoundHound's rapid growth and the long-term trends supporting more AI integration across the economy. 2. Duolingo Online language learning is another fast-growing market that is benefiting from the use of AI. Duolingo (NASDAQ: DUOL) started in 2012 and is currently the top-grossing mobile learning app in Alphabet 's Google Play and the Apple App Store. The company's rapid growth has sent the stock up 241% since its initial public offering in 2021. Duolingo makes it easy and fun to learn new languages, and it's attracting a lot of people. It had 130 million monthly active users in Q1, representing a 33% year-over-year increase. A high percentage of these users are engaging with the app every day, with the company reporting 46.6 million daily actives last quarter, for an increase of 49% year over year. The company uses the standard mobile app business model. Users can download the app for free and then pay for premium content. Duolingo had over 10 million paying users last quarter. This generated $230 million of revenue last quarter, up 38% year over year, while also reporting a healthy profit of $35 million. The online language learning market is expected to grow at an annualized rate of 21% through 2030 to reach $44 billion, according to Mordor Intelligence. AI will be a catalyst for growth, given the added personalization and other enhancements AI brings to the table. Duolingo says its Max subscription service, which brings AI-powered features to the learning experience, is one of its biggest opportunities. However, Duolingo also offers courses in math and music, indicating its long-term opportunity extends well beyond language learning. Content expansion, including the recent launch of chess, is a key part of the company's growth strategy. Duolingo's market cap is currently $21.8 billion at the current $480 share price. For the company to be worth $210 billion and deliver a 10-fold return to investors in 10 years, Duolingo needs to maintain annualized revenue growth of 25% and trade at the same 28x price-to-sales multiple. This implies growth that is marginally higher than the online language learning market. Duolingo's 40%-plus current revenue growth already puts it ahead of the curve. Moreover, its content expansion strategy positions it to grow faster than the market, making it a compelling growth stock to hold for multibagger returns. Should you invest $1,000 in SoundHound AI right now? Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
